MCVRX Mutual Fund

NAV$33.40

Fund Essentials - as of Mar 31, 2026

Net Assets
$46M
Expense Ratio
1.22%
Dividend Yield (Current)
7.27%
Holdings
155
Inception Date
Oct 31, 2003
Fund Family
MFS Investment Management
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+11.43%
1 Year+18.80%
3 Year+12.18%
5 Year+8.26%
10 Year+9.98%

Asset Allocation

Stocks: 98.40%
Cash: 1.61%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
VLOValero Energy Corp1.42%
FLEX:SIFlex Ltd1.41%
-Mfs Institutional Money Market Portfolio1.39%
PCGPg&E Corp.1.26%
PRPermian Resources Corp1.25%
Top 10 Concentration: 12.68%Report Date: Mar 31, 2026
Download all 155 holdings for MCVRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
7.27%
Frequency
Annually
Latest Distribution
$1.71
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how MCVRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

MCVRX Mutual Fund Overview

MCVRX Mutual Fund (MFS Mid Cap Value Fund Class R2) is managed by MFS Investment Management with $45.8M in net assets. MCVRX expense ratio is 1.22%, holding 155 positions across sectors including Industrials, Unknown, Financials. Inception date: 2003-10-31.

MCVRX performance shows a YTD return of 11.43%. The 1-year return is 18.80% and the 5-year return is 8.26%. MCVRX dividend yield stands at 7.27%, paid annually.

MCVRX top holdings include Valero Energy Corp (1.4%), Flex Ltd (1.4%), Mfs Institutional Money Market Portfolio (1.4%), Pg&E Corp. (1.3%), Permian Resources Corp (1.3%). View all MCVRX holdings, sector breakdown, or dividend history.

MCVRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. MCVRX alternatives are available via the screener, along with tax-loss harvesting opportunities.